{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:51:52Z","timestamp":1759179112684},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,1,31]],"date-time":"2006-01-31T00:00:00Z","timestamp":1138665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:p><jats:bold>Abstract: Objective: <\/jats:bold> Hepatic steatosis is a histological feature in patients with chronic hepatitis C (CHC) and adversely affects the virologic response rates to anti\u2010hepatitis C virus (HCV) therapy. The aim of this study is to investigate whether the fatty liver and related factors have impact on the efficacy in CHC treated with peginterferon and ribavirin, and the associations between HCV genotyping and fatty liver.<\/jats:p><jats:p><jats:bold>Methods: <\/jats:bold> Ninety\u2010eight patients received subcutaneously 180\u2003\u03bcg peginterferon \u03b1\u20102a once a week plus ribavirin. HCV genotypes and the levels of plasma insulin of patients were measured. Fatty liver was detected by B ultrasound. The body mass index (BMI), waist\u2010to\u2010hip ratio (WHR) and homeostasis model assessment of insulin resistance (HOMA\u2010IR) were calculated.<\/jats:p><jats:p><jats:bold>Results: <\/jats:bold> Among 98 CHC patients, 38 (38.8%) were infected with genotype 1; 44 (44.9%) with genotype 2; 13 (13.3%) with genotype 3; 3 (3.0%) with indeterminate genotype. The prevalence of fatty liver was 10.5%, 11.4%, 38.5% in patients infected with HCV genotype 1, 2, 3, respectively, which suggested that the distribution of fatty liver in different HCV genotypes was imbalanced (\u03c7<jats:sup>2<\/jats:sup>=6.758, <jats:italic>P<\/jats:italic>=0.034). In univariate analysis, the efficacy of combination therapy was significantly associated with BMI (<jats:italic>P<\/jats:italic>=0.011), WHR (<jats:italic>P<\/jats:italic>=0.024), the levels of plasma insulin (<jats:italic>P<\/jats:italic>=0.001), genotype (<jats:italic>P<\/jats:italic>=0.036), presence of fatty liver (<jats:italic>P<\/jats:italic>=0.028), treatment dosage and duration (<jats:italic>P<\/jats:italic>=0.012) and HOMA\u2010IR (<jats:italic>P<\/jats:italic>=0.002). With binary logistic regression analysis, the plasma insulin levels and HOMA\u2010IR showed independent predictors to the efficacy of antiviral therapy.<\/jats:p><jats:p><jats:bold>Conclusion: <\/jats:bold> The prevalence of fatty liver in HCV genotype 3 was markedly higher than that of other genotypes. The BMI, WHR, the levels of plasma insulin, genotype, presence of fatty liver, treatment dosage and duration and HOMA\u2010IR were associated with the sustained virologic response. The level of plasma insulin and HOMA\u2010IR were independent factors for predicting effect of antiviral therapy.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2005.01219.x","type":"journal-article","created":{"date-parts":[[2006,1,31]],"date-time":"2006-01-31T14:56:02Z","timestamp":1138719362000},"page":"166-172","source":"Crossref","is-referenced-by-count":41,"title":["Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C"],"prefix":"10.1111","volume":"26","author":[{"given":"Yu","family":"Jian Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Shu Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Gui Qiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,1,31]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"125","article-title":"Hepatitis C","volume":"30","author":"Sarbah S A","year":"2000","journal-title":"an update on the silent epidemic"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-132-4-200002150-00008"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840360703"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000135372.10846.2a"},{"issue":"5","key":"e_1_2_5_6_2","first-page":"585","article-title":"Non\u2010alcoholic stetohepatitis (NASH)","volume":"50","author":"Day C P.","year":"2002","journal-title":"where are we now and where are we going?"},{"issue":"3","key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1665-2681(19)32100-3","article-title":"Nonalcoholic fatty liver disease","volume":"3","author":"Lafaine M","year":"2004","journal-title":"Annal Hepatol"},{"issue":"3","key":"e_1_2_5_8_2","first-page":"428","article-title":"Hepatitis C virus induced hypobetalipoproteinemia","volume":"34","author":"Serfaty L","year":"2001","journal-title":"a possible mechanism for steatosis in chronic hepatitis C"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.03.020"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000007778"},{"issue":"8","key":"e_1_2_5_11_2","first-page":"1844","article-title":"Nonalcoholic fatty liver disease","volume":"50","author":"Marchesini G","year":"2001","journal-title":"a feature of the metabolic syndrome"},{"issue":"3","key":"e_1_2_5_12_2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/135965350501000302","article-title":"Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C","volume":"10","author":"Liu C J","year":"2005","journal-title":"Antiviral Ther"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00143-X"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.24432"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.08.032"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50267"},{"issue":"4","key":"e_1_2_5_17_2","first-page":"179A","article-title":"Hyperinsulinemia blocks the inhibition of hepatitis C virus (HCV) replication by interferon","volume":"40","author":"Sanyal A J","year":"2004","journal-title":"a potential mechanism for failure of interferon therapy in subjects with HCV and nonalcoholic liver disease"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50258"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-1702(95)00052-R"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s005350050304"},{"key":"e_1_2_5_21_2","first-page":"43","article-title":"Ultrasonographical diagnosis of fatty liver","volume":"139","author":"Yajima Y","year":"1983","journal-title":"significance of the liver\u2013kidney contrast"},{"key":"e_1_2_5_22_2","first-page":"412","article-title":"Homeostasis model assessment","volume":"28","author":"Matthews D R","year":"1985","journal-title":"insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-76-5-1197"},{"key":"e_1_2_5_24_2","first-page":"72","article-title":"The influnce of HCV genotype on the IFN treatment of patients with chronic hepatitis C","volume":"12","author":"Xie Y","year":"2004","journal-title":"Zhonghua Gangzangbing Zazhi"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840360716"},{"key":"e_1_2_5_26_2","first-page":"S8","article-title":"Vrial factors affecting to the outcome of therapy for chronic hepatitis C","volume":"4","author":"Michael W","year":"2004","journal-title":"Rev Gastroenterol Disord"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.2.288"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/155.4.346"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.35354"},{"key":"e_1_2_5_30_2","first-page":"119","article-title":"Liver steatosis in chronic hepatitis C","volume":"39","author":"Rubbia\u2010Brandt L","year":"2001","journal-title":"a morphological sign suggesting infection with HCV genotype 3"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50350"},{"issue":"2","key":"e_1_2_5_32_2","first-page":"373","article-title":"NASH and insulin resistance","volume":"35","author":"Chitturi S","year":"2002","journal-title":"insulin hypersecretion and specific association with the insulin resistance syndrome"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00271-5"},{"issue":"4","key":"e_1_2_5_34_2","first-page":"42","article-title":"Steatohepatitis","volume":"114","author":"Day C P","year":"1998","journal-title":"a tale of two \u201chits\u201d?"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2005.01219.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2005.01219.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T08:48:59Z","timestamp":1697100539000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2005.01219.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,31]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1111\/j.1478-3231.2005.01219.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2005.01219.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,31]]}}}